Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Version history
  • Article usage
  • Citations to this article

Advertisement

RetractionImmunology Free access | 10.1172/JCI21689R1

A role for proteinase-activated receptor-1 in inflammatory bowel diseases

Nathalie Vergnolle, Laurie Cellars, Andrea Mencarelli, Giovanni Rizzo, Sunita Swaminathan, Paul Beck, Martin Steinhoff, Patricia Andrade-Gordon, Nigel W. Bunnett, Morley D. Hollenberg, John L. Wallace, Giuseppe Cirino, and Stefano Fiorucci

Find articles by Vergnolle, N. in: JCI | PubMed | Google Scholar

Find articles by Cellars, L. in: JCI | PubMed | Google Scholar

Find articles by Mencarelli, A. in: JCI | PubMed | Google Scholar

Find articles by Rizzo, G. in: JCI | PubMed | Google Scholar

Find articles by Swaminathan, S. in: JCI | PubMed | Google Scholar

Find articles by Beck, P. in: JCI | PubMed | Google Scholar

Find articles by Steinhoff, M. in: JCI | PubMed | Google Scholar

Find articles by Andrade-Gordon, P. in: JCI | PubMed | Google Scholar

Find articles by Bunnett, N. in: JCI | PubMed | Google Scholar

Find articles by Hollenberg, M. in: JCI | PubMed | Google Scholar

Find articles by Wallace, J. in: JCI | PubMed | Google Scholar

Find articles by Cirino, G. in: JCI | PubMed | Google Scholar

Find articles by Fiorucci, S. in: JCI | PubMed | Google Scholar

Published July 3, 2006 - More info

Published in Volume 116, Issue 7 on July 3, 2006
J Clin Invest. 2006;116(7):2056–2056. https://doi.org/10.1172/JCI21689R1.
© 2006 The American Society for Clinical Investigation
Published July 3, 2006 - Version history
View PDF

Related article:

A role for proteinase-activated receptor–1 in inflammatory bowel diseases
Nathalie Vergnolle, … , Giuseppe Cirino, Stefano Fiorucci
Nathalie Vergnolle, … , Giuseppe Cirino, Stefano Fiorucci
Article Immunology

A role for proteinase-activated receptor–1 in inflammatory bowel diseases

  • Text
  • PDF
Abstract

Proteinase-activated receptor–1 (PAR1), a G protein–coupled receptor activated by thrombin, is highly expressed in different cell types of the gastrointestinal tract. The activity of thrombin and of other proteinases is significantly increased in the colon of inflammatory bowel disease (IBD) patients. Since PAR1 activation in tissues other than the gut provoked inflammation, we hypothesized that PAR1 activation in the colon is involved in the pathogenesis of IBD. Here, we demonstrate that PAR1 is overexpressed in the colon of IBD patients. In mice, intracolonic administration of PAR1 agonists led to an inflammatory reaction characterized by edema and granulocyte infiltration. This PAR1 activation–induced inflammation was dependent on B and T lymphocytes. Moreover, PAR1 activation exacerbated and prolonged inflammation in a mouse model of IBD induced by the intracolonic administration of trinitrobenzene sulfonic acid (TNBS), while PAR1 antagonism significantly decreased the mortality and severity of colonic inflammation induced by TNBS and dextran sodium sulfate. In these 2 models, colitis development was strongly attenuated by PAR1 deficiency. Taken together, these results imply an important role for PAR1 in the pathogenesis of experimental colitis, supporting the notion that PAR1 inhibition may be beneficial in the context of IBD and possibly in other chronic intestinal inflammatory disorders.

Authors

Nathalie Vergnolle, Laurie Cellars, Andrea Mencarelli, Giovanni Rizzo, Sunita Swaminathan, Paul Beck, Martin Steinhoff, Patricia Andrade-Gordon, Nigel W. Bunnett, Morley D. Hollenberg, John L. Wallace, Giuseppe Cirino, Stefano Fiorucci

×

Original citation: J. Clin. Invest.114:1444 -1456 (2006). doi:10.1172/JCI21689

Citation for this retraction: J. Clin. Invest.116:2056 (2006). doi:10.1172/JCI21689R1

RT-PCR blots published in panel C of Figure 8 of this paper were mistakenly reproduced from a previous publication. The senior author sincerely regrets this error and would like to emphasize that this in no way diminishes the validity of the data contributed by the coauthors of the paper. However, the paper is being retracted in accordance with JCI policy.

The authors apologize for any inconvenience this error has caused.

Version history
  • Version 1 (July 3, 2006): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts